Advances in diagnosis and treatment of latent tuberculosis infection

Journal of the American Board of Family Medicine

Volumn 27, Issue 5, 2014, Pages 704-712

  Chapman, Helena J ^a   Lauzardo, Michael ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Infectious Diseases; Respiratory Tract Diseases

Indexed keywords

GAMMA INTERFERON; ISONIAZID; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ANTIGEN SPECIFICITY; COMORBIDITY; GOLD STANDARD; HUMAN; IN VITRO STUDY; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; REVIEW; TREATMENT OUTCOME; TUBERCULIN TEST; ANALOGS AND DERIVATIVES; DISEASE COURSE; HEALTH; HIV INFECTIONS; IMMUNOCOMPROMISED PATIENT; INTERFERON GAMMA RELEASE ASSAY; PROCEDURES; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES;

ANTITUBERCULAR AGENTS; COMORBIDITY; DISEASE PROGRESSION; GLOBAL HEALTH; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON-GAMMA RELEASE TESTS; ISONIAZID; LATENT TUBERCULOSIS; RIFAMPIN; RISK ASSESSMENT; TUBERCULIN TEST; UNITED STATES;

EID: 84907052033     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2014.05.140062     Document Type: Review

References (77)

1. Glaziou P, Falzon D, Floyd K, Raviglione M. Global epidemiology of tuberculosis. Semin Respir Crit Care Med 2013;34:3-16.
2. Global tuberculosis report 2013. Geneva, Switzerland: World Health Organization; 2013.
3. Lawn SD, Zumla AI. Tuberculosis. Lancet 2011; 378:57-72.
4. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013;368:745-55.
5. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003;362:887-99.
6. Millet JP, Moreno A, Fina L, et al. Factors that influence current tuberculosis epidemiology. Eur Spine J 2013;22(Suppl 4):539-48.
7. Gordin FM, Masur H. Current approaches to tuberculosis in the United States. JAMA 2012;308:283-9.
8. Barker RD. Clinical tuberculosis. Medicine 2008;36: 300-5.
9. Fact sheet: trends in tuberculosis, 2012. Atlanta, GA: Centers for Disease Control and Prevention (CDC); 2013. Available from: http://www.cdc.gov/tb/publications/factsheets/statistics/TBTrends.htm. Accessed July 20, 2014.
10. Inge LD, Wilson JW. Update on the treatment of tuberculosis. Am Fam Physician 2008;78:457-65, 469-70.
11. ATS. Diagnostic standards and classification of tuberculosis in adults and children. Joint statement of the American Thoracic Society and the Centers for Disease Control and Prevention, July 1999. Endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161(4 Pt 1):1376-95.
12. Hauck FR, Neese BH, Panchal AS, El-Amin W. Identification and management of latent tuberculosis infection. Am Fam Physician 2009;79:879-86.
13. Taylor Z, Nolan CM, Blumberg HM; American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, Centers for Disease Control and Prevention, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005;54(RR-12):1-81.
14. Centers for Disease Control and Prevention (CDC). Trends in tuberculosis-United States, 2007. MMWR Morb Mortal Wkly Rep 2008;57:281-5.
15. Centers for Disease Control and Prevention (CDC). Trends in tuberculosis-United States, 2012. MMWR Morb Mortal Wkly Rep 2013;62:201-5.
16. Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Eng J Med 2011;364:1441-8.
17. Schwartzman K. Latest tuberculosis infection: old problem, new priorities. CMAJ 2002;166:759-61.
18. Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR Jr. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol 2014;179:216-25.
19. Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med 2007;13:175-82.
20. Campos-Outcalt D. Tuberculosis: old problem, new concerns. J Fam Pract 2003;52:792-8.
21. Trajman A, Steffen RE, Menzies D. Interferongamma release assays versus tuberculin skin testing for the diagnosis of latent tuberculosis infection: an overview of the evidence. Pulm Med 2013;2013: 601737.
22. Madariaga MG, Jalali Z, Swindells S. Clinical utility of interferon gamma assay in the diagnosis of tuberculosis. J Am Board Fam Med 2007;20:540-7.
23. Schluger NW. Advances in the diagnostics of latent tuberculosis infection. Semin Respir Crit Care Med 2013;34:60-6.
24. Hwang LY, Grimes CZ, Beasley RP, Graviss EA. Latent tuberculosis infections in hard-to-reach drug using population-detection, prevention and control. Tuberculosis (Edinb) 2009;89(Suppl 1):S41-5.
25. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000;356:1099-104.
26. Abubakar I, Stagg HR, Whitworth H, Lalvani A. How should I interpret an interferon gamma release assay result for tuberculosis infection? Thorax 2013; 68:298-301.
27. Mazurek GH, Villarino ME; Division of Tuberculosis Elimination; National Center for HIV, STD, and TB Prevention; Centers for Disease Control and Prevention. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2003; 52(RR-02):15-8.
28. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A; Division of Tuberculosis Elimination; National Center for HIV, STD, and TB Prevention; Centers for Disease Control and Prevention. Guidelines for using the QuantiFERON -TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005;54(RR-15):49-55.
29. Simpson T, Fox J, Crouse K, Field K. Screening for Mycobacterium tuberculosis using an interferongamma release assay. J Public Health Manag Pract 2012;18:E19-25.
30. Pollock L, Basu Roy R, Kampmann B. How to use: interferon gamma release assays for tuberculosis. Arch Dis Child Educ Pract Ed 2013;98:99-105.
31. Lavlani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest 2007;131:1898 -906.
32. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn 2006;6:413-22.
33. Linas BP, Wong AY, Freedberg KA, Horsburgh CR Jr. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011;184:590-601.
34. Reported tuberculosis in the United States, 2012. Atlanta, GA: Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services; 2013.
35. Triverio PA, Bridevauz PO, Roux-Lombard P, et al. Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients. Nephrol Dial Transplant 2009;24:1952-6.
36. Winthrop KL. Weinblatt ME, Daley CL. You cant always get what you want, but if you try sometimes (with two tests-TST and IGRA-for tuberculosis) you get what you need. Ann Rheum Dis 2012;71: 1757-60.
37. Diel R, Loddenkemper R, Nienhaus A. Evidencebased comparison of commercial interferon release assays for detecting active TB: a metaanalysis. Chest 2010;137:952-68.
38. Diel R, Goletti D, Ferrara G, et al. Interferon release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011;37:88-99.
39. Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761-76.
40. Pinto LM, Grenier J, Schumacher SG, Denkinger CM, Steingart KR, Pai M. Immunodiagnosis of tuberculosis: state of the art. Med Princ Pract 2012;21: 4-13.
41. Chiapphi E, Fossi F, Bonsignori F, Sollai S, Galli L, de Martino M. Utility of interferon-gamma release assay results to monitor anti-tubercular treatment in adults and children. Clin Ther 2012;34:1041-8.
42. National Collaborating Centre for Chronic Conditions. Tuberculosis. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. Clinical guideline no. 117. London: National Institute for Health and Clinical Excellence (NICE); 2011.
43. Mandalakas AM, Detjen AK, Hesseling AC, Benedetti A, Menzies D. Interferon-gamma release assays and childhood tuberculosis: systematic review and metaanalysis. Int J Tuberc Lung Dis 2011;15:1018-32.
44. Grant J, Jastrzebski J, Johnston J, et al. Interferongamma release assays are a better tuberculosis screening test for hemodialysis patients: a study and review of the literature. Can J Infect Dis Med Microbiol 2012;23:114-6.
45. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K; IGRA Expert Committee; Centers for Disease Control and Prevention. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010;58(RR-5): 1-25.
46. Starke JR. Interferon release assays for the diagnosis of tuberculosis infection in children. J Pediatr 2012;161:581-2.
47. van Zyl-Smit RN, Pai M, Peprah K, et al. Withinsubject variability and boosting of T-cell interferon responses after tuberculin skin testing. Am J Respir Crit Care Med 2009;180:49-58.
48. Ringshausen FC, Nienhaus A, Torres Costa J, et al. Within-subject variability of Mycobacterium tuberculosis-specific gamma interferon responses in German health care workers. Clin Vaccine Immunol 2011;18:1176-82.
49. Tsai KS, Chang HL, Chien ST, et al. Childhood tuberculosis: epidemiology, diagnosis, treatment, and vaccination. Pediatr Neonatol 2013;54:295-302.
50. Takenami I, Loureiro C, Machado A Jr, Emodi K, Riley LW, Arruda S. Blood cells and interferongamma levels correlation in latent tuberculosis infection. ISRN Pulmonol 2013;2013. pii:256148.
51. Sridhar S, Pollock K, Lalvani A. Redefining latent tuberculosis. Future Microbiol 2011;6:1021-35.
52. Smith R, Cattamanchi A, Steingart KR, et al. Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 2011;23:377-84.
53. Alexander TS, Miller MB, Gilligan P. Should interferon gamma release assays become the standard method for screening patients for Mycobacterium tuberculosis infections in the United States. J Clin Microbiol 2011;49:2086-92.
54. Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. Test variability of the QuantiFERON-TB Gold In-Tube assay in clinical practice. Am J Resp Crit Care Med 2013;187: 206-11.
55. Nienhaus A, Ringshausen FC, Costa JT, Schablon A, Tripodi D. IFN release assay versus tuberculin skin test for monitoring TB infection in healthcare workers. Expert Rev Anti Infect Ther 2013;11:37-48.
56. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000;49(RR-6):1-54.
57. Vernon A. Treatment of latent tuberculosis infection. Semin Respir Crit Care Med 2013;34:67-86.
58. Latent tuberculosis infection: a guide for primary health care providers. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2013. Available from: http://www.cdc.gov/tb/publications/ltbi/default.htm. Accessed July 20, 2014.
59. Blumberg HM, Leonard MK Jr, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005;293:2776-84.
60. Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology 2010;15: 603-22.
61. Denholm JT, McBryde ES. The use of anti-tuberculosis therapy for latent TB infection. Infect Drug Resist 2010;3:63-72.
62. Isoniazid. Tuberculosis (Edinb) 2008;88:112-6.
63. Parekh M, Schluger N. Treatment of latent tuberculosis infection. Ther Adv Respir Dis 2013;7: 351-6.
64. Ahmad S. New approaches in the diagnosis and treatment of latent tuberculosis infection. Respir Res 2010;11:169.
65. Rifampin. Tuberculosis (Edinb) 2008;88:151-4.
66. Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis. Arch Intern Med 2006;166:1863-70.
67. Esfahani K, Aspler A, Menzies D, Schwartzman K. Potential cost-effectiveness of rifampin vs isoniazid for latent tuberculosis: implications for future clinical trials. Int J Tuberc Lung Dis 2011;15:1340-6.
68. Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011;60:1650-3.
69. Sterling TR, Villarino ME, Borisov AS, et al. TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365: 2155-66.
70. Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013;7:CD007545.
71. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 2004;17:59-67.
72. Dooley KE, Nuermberger EL, Diacon AH. Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS 2013;8:579-85.
73. Ho MJ. Sociocultural aspects of tuberculosis: a literature review and a case study of immigrant tuberculosis. Soc Sci Med 2004;59:753-62.
74. Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009;68:2240-6.
75. Hargreaves JR, Boccia D, Evans CA, Adato M, Petticrew M, Porter JD. The social determinants of tuberculosis: from evidence to action. Am J Pub Health 2011;101:654-62.
76. Bates I, Fenton C, Gruber J, et al. Vulnerability to malaria, tuberculosis, and HIV/AIDS infection and disease. Part 1: determinants operating at individual and household level. Lancet Infect Dis 2004;4: 267-77.
77. Colson PW, Hirsch-Moverman Y, Bethel J, et al. Tuberculosis Epidemiologic Studies Consortium. Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada. Int J Tuberc Lung Dis 2013;17: 473-9